These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9707017)

  • 1. Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries.
    Clarke E; Potter MN; Hale G; Waldmann H; Lankester A; Cornish JM; Steward CG; Marks DI; Oakhill A; Pamphilon DH
    Bone Marrow Transplant; 1998 Jul; 22(2):117-24. PubMed ID: 9707017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A laboratory comparison of T cell depletion by CD34+ cell immunoaffinity selection and in vitro Campath-1M treatment: clinical implications for bone marrow transplantation and donor leukocyte therapy.
    Clarke E; Potter MN; Oakhill A; Cornish JM; Steward CG; Pamphilon DH
    Bone Marrow Transplant; 1997 Oct; 20(7):599-605. PubMed ID: 9337063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1.
    Dreger P; Viehmann K; Steinmann J; Eckstein V; Müller-Ruchholtz W; Löffler H; Schmitz N
    Exp Hematol; 1995 Feb; 23(2):147-54. PubMed ID: 7530212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia.
    Lowdell MW; Craston R; Ray N; Koh M; Galatowicz G; Prentice HG
    Bone Marrow Transplant; 1998 Apr; 21(7):679-86. PubMed ID: 9578307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
    Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR
    Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell-depletion equivalent to elutriation.
    Cottler-Fox M; Cipolone K; Yu M; Berenson R; O'Shaughnessy J; Dunbar C
    Exp Hematol; 1995 Apr; 23(4):320-2. PubMed ID: 7534711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
    Hale G; Waldmann H
    Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counterflow centrifugation allows addition of appropriate numbers of T cells to allogeneic marrow and blood stem cell grafts to prevent severe GVHD without substantial loss of mature and immature progenitor cells.
    Preijers FW; van Hennik PB; Schattenberg A; Ruijs P; Ploemacher RE; de Witte T
    Bone Marrow Transplant; 1999 May; 23(10):1061-70. PubMed ID: 10373074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID).
    Dickinson AM; Reid MM; Abinun M; Peak J; Brigham K; Dunn J; Cant AJ
    Bone Marrow Transplant; 1997 Feb; 19(4):323-9. PubMed ID: 9051241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two different methods for CD34+ selection and T cell depletion in peripheral blood stem cell grafts--our experiences with CellPro, E rosetting and CliniMACS technique.
    Poloucková A; Vodvárková A; Kobylka P; Hrubá A; Gasová Z; Marinov I; Fales I; Sedlácek P; Kozák T; Starý J
    Neoplasma; 2001; 48(5):374-81. PubMed ID: 11845982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined CD34 positive plus CD2 negative selection for effective T-cell depletion as GvHD-prophylaxis in HLA-nonidentical blood progenitor cell transplantation.
    Wiesneth M; Schreiner T; Friedrich W; Müller S; Maccari B; Erne E; Bischof C; Kubanek B
    Transfus Sci; 1996 Dec; 17(4):629-35. PubMed ID: 10168563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purging and haemopoietic progenitor cell selection by CD34+ cell separation.
    Krüger W; Gruber M; Hennings S; Fehse N; Fehse B; Gutensohn K; Kröger N; Zander AR
    Bone Marrow Transplant; 1998 Apr; 21(7):665-71. PubMed ID: 9578305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience.
    Watanabe T; Kawano Y; Watanabe A; Takaue Y
    Haematologica; 1999 Feb; 84(2):167-76. PubMed ID: 10091416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
    Cobbold SP; Hale G; Clark MR; Waldmann H
    Prog Clin Biol Res; 1990; 333():139-51; discussion 152-4. PubMed ID: 2308978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
    Naparstek E; Delukina M; Or R; Nagler A; Kapelushnik J; Varadi G; Strauss N; Cividalli G; Aker M; Brautbar C; Waldmann H; Hale G; Slavin S
    Exp Hematol; 1999 Jul; 27(7):1210-8. PubMed ID: 10390197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive selection of hematopoietic CD34+ stem cells provides 'indirect purging' of CD34- lymphoid cells and the purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins.
    Lemoli RM; Tazzari PL; Fortuna A; Bolognesi A; Gulati SC; Stirpe F; Tura S
    Bone Marrow Transplant; 1994 Apr; 13(4):465-71. PubMed ID: 7517259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation.
    Chakraverty R; Robinson S; Peggs K; Kottaridis PD; Watts MJ; Ings SJ; Hale G; Waldmann H; Linch DC; Goldstone AH; Mackinnon S
    Bone Marrow Transplant; 2001 Nov; 28(9):827-34. PubMed ID: 11781642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.